RESUMO
Information on the recent herpetological and related parasitological collections are very rarely available for Afghanistan. We examined two species of the family Agamidae, Laudakia nuristanica and Paralaudakia caucasia for the presence of the intestinal helminth fauna. Overall, we examined 13 specimens of these lizards and found three species of helminths (Abbreviata achari, Thelandros masaae, T. taylori) in a single specimen of L. nuristanica and four species (A. achari, T. baylisi, T. taylori, P. kasauli) in three specimens of P. caucasia. Here in, we present the first report on the helminth fauna from L. nuristanica, record a new helminth host for P. caucasia and three new country records for the helminth fauna of Afghanistan.
Assuntos
Influenza Humana , Aspergilose Pulmonar Invasiva , Antifúngicos/uso terapêutico , Humanos , Influenza Humana/complicações , Influenza Humana/tratamento farmacológico , Influenza Humana/epidemiologia , Aspergilose Pulmonar Invasiva/diagnóstico , Aspergilose Pulmonar Invasiva/tratamento farmacológico , Aspergilose Pulmonar Invasiva/epidemiologiaRESUMO
The true burden of fungal infection in Pakistan is unknown. High-risk populations for fungal infections [tuberculosis (TB), diabetes, chronic respiratory diseases, asthma, cancer, transplant and human immunodeficiency virus (HIV) infection] are numerous. Here, we estimate the burden of fungal infections to highlight their public health significance. Whole and at-risk population estimates were obtained from the WHO (TB), BREATHE study (COPD), UNAIDS (HIV), GLOBOCAN (cancer) and Heartfile (diabetes). Published data from Pakistan reporting fungal infections rates in general and specific populations were reviewed and used when applicable. Estimates were made for the whole population or specific populations at risk, as previously described in the LIFE methodology. Of the 184,500,000 people in Pakistan, an estimated 3,280,549 (1.78%) are affected by a serious fungal infection, omitting all cutaneous infection, oral candidiasis and allergic fungal sinusitis, which we could not estimate. Compared with other countries, the rates of candidaemia (21/100,000) and mucormycosis (14/100,000) are estimated to be very high, and are based on data from India. Chronic pulmonary aspergillosis rates are estimated to be high (39/100,000) because of the high TB burden. Invasive aspergillosis was estimated to be around 5.9/100,000. Fungal keratitis is also problematic in Pakistan, with an estimated rate of 44/100,000. Pakistan probably has a high rate of certain life- or sight-threatening fungal infections.
Assuntos
Micoses/epidemiologia , Micoses/patologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Pré-Escolar , Comorbidade , Feminino , Humanos , Incidência , Lactente , Recém-Nascido , Masculino , Pessoa de Meia-Idade , Paquistão/epidemiologia , Prevalência , Medição de Risco , Adulto JovemRESUMO
We analysed susceptibility of multidrug-resistant organisms (MDROs) including New Delhi metallo-beta-lactamase-1 positive Enterobacteriaceae to chlorhexidine and compared results to their susceptible counterparts. Susceptibilities of chlorhexidine digluconate in a standard (CHX-S) preparation and two commercial disinfectants containing different CHX concentrations (2% w/v and 4% w/w) were performed. MDROs had narrower range of higher CHX-S minimum inhibitory concentrations (MICs) as compared to pan-sensitive organisms. The MIC values for commercial disinfectants products for MDROs were many folds higher (20-600 times), than CHX-S for in vitro use. Increasing antibiotic resistance among bacterial isolates can be an indirect marker of reduced susceptibility to chlorhexidine in hospital setting.
Assuntos
Anti-Infecciosos Locais/farmacologia , Clorexidina/farmacologia , Farmacorresistência Bacteriana , Infecções por Enterobacteriaceae/microbiologia , Enterobacteriaceae/efeitos dos fármacos , Enterobacteriaceae/enzimologia , beta-Lactamases/metabolismo , Enterobacteriaceae/isolamento & purificação , Humanos , Testes de Sensibilidade Microbiana , Paquistão , Centros de Atenção TerciáriaRESUMO
The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 15 countries in Europe, the Middle East and Asia, and the relative impact of two scenarios was considered: increased treatment efficacy while holding the annual number of treated patients constant and increased treatment efficacy and an increased annual number of treated patients. Increasing levels of diagnosis and treatment, in combination with improved treatment efficacy, were critical for achieving substantial reductions in disease burden. A 90% reduction in total HCV infections within 15 years is feasible in most countries studied, but it required a coordinated effort to introduce harm reduction programmes to reduce new infections, screening to identify those already infected and treatment with high cure rate therapies. This suggests that increased capacity for screening and treatment will be critical in many countries. Birth cohort screening is a helpful tool for maximizing resources. Among European countries, the majority of patients were born between 1940 and 1985. A wider range of birth cohorts was seen in the Middle East and Asia (between 1925 and 1995).
Assuntos
Controle de Doenças Transmissíveis/métodos , Hepatite C Crônica/epidemiologia , Hepatite C Crônica/prevenção & controle , Modelos Estatísticos , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Antivirais/uso terapêutico , Ásia/epidemiologia , Criança , Pré-Escolar , Testes Diagnósticos de Rotina/métodos , Testes Diagnósticos de Rotina/estatística & dados numéricos , Uso de Medicamentos , Europa (Continente)/epidemiologia , Feminino , Hepatite C Crônica/diagnóstico , Hepatite C Crônica/terapia , Humanos , Incidência , Lactente , Recém-Nascido , Transplante de Fígado , Masculino , Pessoa de Meia-Idade , Oriente Médio/epidemiologia , Prevalência , Adulto JovemRESUMO
Detailed, country-specific epidemiological data are needed to characterize the burden of chronic hepatitis C virus (HCV) infection around the world. With new treatment options available, policy makers and public health officials must reconsider national strategies for infection control. In this study of 15 countries, published and unpublished data on HCV prevalence, viraemia, genotype, age and gender distribution, liver transplants and diagnosis and treatment rates were gathered from the literature and validated by expert consensus in each country. Viraemic prevalence in this study ranged from 0.2% in Iran and Lebanon to 4.2% in Pakistan. The largest viraemic populations were in Pakistan (7 001 000 cases) and Indonesia (3 187 000 cases). Injection drug use (IDU) and a historically unsafe blood supply were major risk factors in most countries. Diagnosis, treatment and liver transplant rates varied widely between countries. However, comparison across countries was difficult as the number of cases changes over time. Access to reliable data on measures such as these is critical for the development of future strategies to manage the disease burden.
Assuntos
Hepacivirus/isolamento & purificação , Hepatite C Crônica/epidemiologia , Hepatite C Crônica/virologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Antivirais/uso terapêutico , Criança , Pré-Escolar , Feminino , Genótipo , Saúde Global , Hepacivirus/classificação , Hepatite C Crônica/diagnóstico , Hepatite C Crônica/terapia , Humanos , Lactente , Recém-Nascido , Transplante de Fígado , Masculino , Pessoa de Meia-Idade , Prevalência , Adulto JovemRESUMO
This study reports for the first time, to our knowledge, descriptive epidemiological data for 188 invasive Candida isolates from Pakistan, including species identification and antifungal susceptibility against fluconazole, itraconazole, voriconazole, caspofungin, micafungin, anidulafungin and amphotericin. Risk factors for invasive candidiasis (IC) were determined for 96 patients from Karachi, Pakistan. In adults and neonates, Candida tropicalis (38 and 36â%, respectively) was the most common species, followed in adults by Candida parapsilosis (17.8â%), Candida glabrata (15.9â%) and Candida albicans (12.3â%). C. albicans (21â%) was the second most common in neonates. In children, C. albicans (31.9â%), C. tropicalis (26.4â%) and C. parapsilosis (19.4â%) were the most common. C. albicans IC was significantly associated with paediatric age [crude odds ratio (COR) 3.46, 95â% confidence interval (CI) 1.63-7.32]. Rare species made up 17.5â% of the total isolates studied. Resistance to fluconazole was seen in C. glabrata (15â.0%) and Candida krusei (100â.0%). Only one isolate (C. glabrata) was resistant to all three echinocandins. Low MICs of fluconazole for 98â% (184/188) of isolates tested support its continued use as an empiric therapy for IC. Non-C. albicans IC was associated with the use of ß-lactam inhibitor combinations (COR 3.16, 95â% CI 1.05-9.57). Use of healthcare devices was documented in 85.4â% of IC patients, whilst 75â.0% had been admitted to special care units. Surprisingly, 66.7â% of patients with IC were not obviously immunosuppressed. The high frequency of modifiable risk factors in this population indicates that candidaemia can be reduced with stringent antibiotic and infection control measures. These data will be useful for empiric selection of antifungals in Karachi, and contribute to global assessments of antifungal resistance.